Skip header and navigation

9 records – page 1 of 1.

5-Aminosalicylate (5-ASA) for inflammatory bowel disease (IBD)

https://libcat.nshealth.ca/en/permalink/chpams35397
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program. Halifax, NS: Nova Scotia Health Authority , 2022.
Pamphlet Number
1483
Available Online
View Pamphlet
5-aminosalicylate (5-ASA) is a medication often used to treat inflammatory bowel disease (IBD). It helps to controll active ulcerative colitis, or Crohn’s colitis and keep mild to moderate ulcerative colitis in remission (period of recovery). Topics include: what does 5-ASA do, which 5-ASA you should take, how to take 5-ASA, what other medications you can take, and how 5-ASA will help. The pamphlet also describes side effects and how long you will need to take 5-ASA.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
Alternate Title
5-Aminosalicylate (5-ASA) for IBD
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2022
Format
Pamphlet
Language
English
Physical Description
1 electronic document (5 p.) : digital, PDF file
Subjects (MeSH)
Inflammatory Bowel Diseases - drug therapy
Crohn Disease - drug therapy
Colitis - drug therapy
Subjects (LCSH)
Inflammatory bowel diseases
Crohn's disease
Colitis
Abstract
5-aminosalicylate (5-ASA) is a medication often used to treat inflammatory bowel disease (IBD). It helps to controll active ulcerative colitis, or Crohn’s colitis and keep mild to moderate ulcerative colitis in remission (period of recovery). Topics include: what does 5-ASA do, which 5-ASA you should take, how to take 5-ASA, what other medications you can take, and how 5-ASA will help. The pamphlet also describes side effects and how long you will need to take 5-ASA.
Notes
Previous title: 5-Aminosalicylate (5-ASA)
Responsibility
Prepared by: Nova Scotia Collaborative IBD Program
Pamphlet Number
1483
Less detail

Adalimumab therapy for inflammatory bowel disease (IBD)

https://libcat.nshealth.ca/en/permalink/chpams35127
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program. Halifax, NS: Nova Scotia Health Authority , 2022.
Pamphlet Number
1207
Available Online
View Pamphlet
Your health care provider feels that treatment with adalimumab may help you manage your inflammatory bowel disease (IBD). This pamphlet describes what adalimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
Alternate Title
Adalimumab therapy for IBD
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2022
Format
Pamphlet
Language
English
Physical Description
1 electronic document (11 p.) : digital, PDF file
Subjects (MeSH)
Adalimumab
Inflammatory Bowel Diseases - drug therapy
Subjects (LCSH)
Inflammatory bowel diseases
Specialty
Medications
Abstract
Your health care provider feels that treatment with adalimumab may help you manage your inflammatory bowel disease (IBD). This pamphlet describes what adalimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Notes
Previous title: Adalimumab (Humira) therapy
Responsibility
Prepared by: Nova Scotia Collaborative IBD Program
Pamphlet Number
1207
Less detail

Corticosteroid therapy for inflammatory bowel disease (IBD)

https://libcat.nshealth.ca/en/permalink/chpams35480
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program. Halifax, NS: Nova Scotia Health Authority , 2024.
Pamphlet Number
1546
Available Online
View Pamphlet
A corticosteroid medication may help you manage your inflammatory bowel disease (IBD). This pamphlet explains what corticosteroids are, how well they work, and how they are given. Information about precautions, possible side effects, and what to expect after your treatment is included.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program
Alternate Title
Corticosteroid therapy for IBD
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2024
Format
Pamphlet
Language
English
Physical Description
1 electronic document (10 p.) : digital, PDF file
Subjects (MeSH)
Inflammatory Bowel Diseases - drug therapy
Prednisone
Subjects (LCSH)
Inflammatory bowel diseases
Prednisone
Specialty
Medications
Abstract
A corticosteroid medication may help you manage your inflammatory bowel disease (IBD). This pamphlet explains what corticosteroids are, how well they work, and how they are given. Information about precautions, possible side effects, and what to expect after your treatment is included.
Notes
This pamphlet replaced pamphlet 1139: Prednisone Therapy
Previous title: Corticosteroid therapy in inflammatory bowel disease (IBD)
Responsibility
Prepared by: Nova Scotia Collaborative Inflammatory Bowel Disease Program
Pamphlet Number
1546
Less detail

Golimumab (Simponi®) for inflammatory bowel disease (IBD)

https://libcat.nshealth.ca/en/permalink/chpams35651
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program. Halifax, NS: Nova Scotia Health Authority , 2022.
Pamphlet Number
1641
Available Online
View Pamphlet
Your health care provider feels that treatment with golimumab may help you manage your inflammatory bowel disease (IBD). This pamphlet describes what golimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
Alternate Title
Golimumab (Simponi®) for IBD
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2022
Format
Pamphlet
Language
English
Physical Description
1 electronic document (12 p.) : digital, PDF file
Subjects (MeSH)
Golimumab
Inflammatory Bowel Diseases - drug therapy
Subjects (LCSH)
Inflammatory bowel diseases
Specialty
Medications
Abstract
Your health care provider feels that treatment with golimumab may help you manage your inflammatory bowel disease (IBD). This pamphlet describes what golimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Notes
Previous title: Golimumab (Simponi) therapy
Responsibility
Prepared by: Nova Scotia Collaborative IBD Program
Pamphlet Number
1641
Less detail

Infliximab therapy for inflammatory bowel disease (IBD)

https://libcat.nshealth.ca/en/permalink/chpams34944
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program. Halifax, NS: Nova Scotia Health Authority , 2022.
Pamphlet Number
1140
Available Online
View Pamphlet
Your health care provider feels that treatment with infliximab may help you to manage your inflammatory bowel disease (IBD). This pamphlet describes what infliximab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
Alternate Title
Infliximab therapy for IBD
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2022
Format
Pamphlet
Language
English
Physical Description
1 electronic document (12 p.) : digital, PDF file
Subjects (MeSH)
Inflammatory Bowel Diseases - drug therapy
Infliximab
Subjects (LCSH)
Inflammatory bowel diseases
Infliximab
Abstract
Your health care provider feels that treatment with infliximab may help you to manage your inflammatory bowel disease (IBD). This pamphlet describes what infliximab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Notes
Previous title: Infliximab (Remicade) therapy
Responsibility
Prepared by: Nova Scotia Collaborative IBD Program
Pamphlet Number
1140
Less detail

Methotrexate (MTX) therapy for inflammatory bowel disease (IBD)

https://libcat.nshealth.ca/en/permalink/chpams34942
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program. Halifax, NS: Nova Scotia Health Authority , 2024.
Pamphlet Number
1138
Available Online
View Pamphlet
Methotrexate (MTX) may help you manage your over-active immune response caused by your inflammatory bowel disease (IBD). This pamphlet gives information about what MTX is, combination therapy in IBD, who should not take MTX, how MTX is given, and possible side effects, and what you can do to lower the chance of side effects.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program
Alternate Title
Methotrexate (MTX) therapy for IBD
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2024
Format
Pamphlet
Language
English
Physical Description
1 electronic document (13 p.) : digital, PDF file
Subjects (MeSH)
Methotrexate
Inflammatory Bowel Diseases
Immunosuppressive Agents
Subjects (LCSH)
Methotrexate
Immunosuppressive agents
Inflammatory bowel diseases
Specialty
Medications
Abstract
Methotrexate (MTX) may help you manage your over-active immune response caused by your inflammatory bowel disease (IBD). This pamphlet gives information about what MTX is, combination therapy in IBD, who should not take MTX, how MTX is given, and possible side effects, and what you can do to lower the chance of side effects.
Responsibility
Prepared by: Nova Scotia Collaborative Inflammatory Bowel Disease Program
Pamphlet Number
1138
Less detail

Risankizumab (Skyrizi®) therapy for inflammatory bowel disease (IBD)

https://libcat.nshealth.ca/en/permalink/chpams38191
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program. Halifax, NS: Nova Scotia Health Authority , 2023.
Pamphlet Number
2345
Available Online
View Pamphlet
Risankizumab is a biologic medication. A biologic medication is a type of medication that treats inflammation. This pamphlet explains how risankizumab works, how it is given, and how long you can expect to take it. Precautions, side effects, and what to expect after treatment are explained. Side effects that require contacting your primary health care provider are listed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program
Alternate Title
Risankizumab (Skyrizi®) therapy for IBD
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2023
Format
Pamphlet
Language
English
Physical Description
1 electronic document (9 p.) : digital, PDF file
Subjects (MeSH)
Inflammatory Bowel Diseases - drug therapy
Subjects (LCSH)
Inflammatory bowel diseases
Specialty
Gastrointestinal System
Medications
Abstract
Risankizumab is a biologic medication. A biologic medication is a type of medication that treats inflammation. This pamphlet explains how risankizumab works, how it is given, and how long you can expect to take it. Precautions, side effects, and what to expect after treatment are explained. Side effects that require contacting your primary health care provider are listed.
Responsibility
Prepared by: Nova Scotia Collaborative IBD Program
Pamphlet Number
2345
Less detail

Ulcerative proctitis

https://libcat.nshealth.ca/en/permalink/chpams35311
Nova Scotia Health Authority. GI Clinic. Halifax, NS: Nova Scotia Health Authority , 2021.
Pamphlet Number
1422
Available Online
View Pamphlet
Ulcerative proctitis is a type of inflammatory bowel disease. Inflammatory bowel disease (IBD) is the general name for diseases that cause inflammation (swelling and irritation) in the intestines (“gut”). It includes ulcerative proctitis, Crohn’s disease, and ulcerative colitis. How this condition is diagnosed as well as the symptoms and treatments are reviewed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. GI Clinic
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2021
Format
Pamphlet
Language
English
Physical Description
1 electronic document (4 p.) : digital, PDF file
Subjects (MeSH)
Colitis, Ulcerative
Inflammatory Bowel Diseases
Subjects (LCSH)
Ulcerative colitis
Inflammatory bowel diseases
Abstract
Ulcerative proctitis is a type of inflammatory bowel disease. Inflammatory bowel disease (IBD) is the general name for diseases that cause inflammation (swelling and irritation) in the intestines (“gut”). It includes ulcerative proctitis, Crohn’s disease, and ulcerative colitis. How this condition is diagnosed as well as the symptoms and treatments are reviewed.
Responsibility
Prepared by: GI Clinic
Pamphlet Number
1422
Less detail

Ustekinumab (Stelara) therapy

https://libcat.nshealth.ca/en/permalink/chpams35722
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program. Halifax, NS: Nova Scotia Health Authority , 2022.
Pamphlet Number
1695
Available Online
View Pamphlet
Your IBD health care provider believes treatment with a medication called ustekinumab may help to manage your inflammatory bowel disease (IBD). The brand name for ustekinumab is Stelara®. This pamphlet will give you basic information about ustekinumab to help you make an informed decision about whether or not to use this treatment. Topics include what ustekinumab is, how it works, how it is given, how long you will need to take it, and how much it will cost. Considerations before you start taki…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2022
Format
Pamphlet
Language
English
Physical Description
1 electronic document (10 p.) : digital, PDF file
Subjects (MeSH)
Ustekinumab
Inflammatory Bowel Diseases - drug therapy
Subjects (LCSH)
Inflammatory bowel diseases
Crohn's disease
Ulcerative colitis
Specialty
Medications
Abstract
Your IBD health care provider believes treatment with a medication called ustekinumab may help to manage your inflammatory bowel disease (IBD). The brand name for ustekinumab is Stelara®. This pamphlet will give you basic information about ustekinumab to help you make an informed decision about whether or not to use this treatment. Topics include what ustekinumab is, how it works, how it is given, how long you will need to take it, and how much it will cost. Considerations before you start taking ustekinumab and while you are taking it are listed. Possible side effects, information about pregnancy and breast/chest feeding, and other important things to know are included.
Notes
Previous title: Ustekinumab (Stelara) therapy for Crohn's disease
Responsibility
Prepared by: Nova Scotia Collaborative IBD Program
Pamphlet Number
1695
Less detail

9 records – page 1 of 1.